About us

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States, and we have a strong pipeline of asthma and COPD treatments in development.

Our asthma management products

Our market-leading NIOX® products are used by specialists around the world to aid asthma diagnosis and management. We sell NIOX® direct in the United States, United Kingdom and Germany, and we are strengthening our presence in Europe and China. Our NIOX® products are also supplied in many other countries through our international network of partners.

Our US commercial collaboration

We collaborate with AstraZeneca in the United States, where we promote the COPD product Tudorza®. We also have the US commercial rights to Duaklir®*, for which AstraZeneca is planning a New Drug Application for H1 2018. Both products feature the novel Pressair® device. As part of our collaboration we have doubled our US salesforce and strengthened our commercial team.

Our respiratory pipeline

Our lead asthma product targeting substitution of GSK’s Flixotide® pMDI was approved in the UK, and we anticipate filing for UK regulatory approval for our product targeting direct substitution of Seretide® pMDI in 2019. We are also developing a number of chronic obstructive pulmonary disease treatments, including novel formulations of currently approved drugs and a substitute for Spiriva Handihaler®.

Our history

Circassia was established in 2006, and in March 2014 we completed an initial public offering on the London Stock Exchange.  In June 2015, we completed the acquisitions of Aerocrine and Prosonix as part of our strategy to independently commercialize our products and broaden our pipeline, and in April 2017 we established a commercial collaboration with AstraZeneca in the United States.

*The Duaklir® trademark is registered in the United States; the mark is not currently approved for use by the FDA.